GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quest PharmaTech Inc (TSXV:QPT) » Definitions » EV-to-FCF

Quest PharmaTech (TSXV:QPT) EV-to-FCF : -8.99 (As of May. 22, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Quest PharmaTech EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Quest PharmaTech's Enterprise Value is C$4.29 Mil. Quest PharmaTech's Free Cash Flow for the trailing twelve months (TTM) ended in Oct. 2023 was C$-0.48 Mil. Therefore, Quest PharmaTech's EV-to-FCF for today is -8.99.

The historical rank and industry rank for Quest PharmaTech's EV-to-FCF or its related term are showing as below:

TSXV:QPT' s EV-to-FCF Range Over the Past 10 Years
Min: -22.51   Med: -7.63   Max: -1.77
Current: -8.99

During the past 13 years, the highest EV-to-FCF of Quest PharmaTech was -1.77. The lowest was -22.51. And the median was -7.63.

TSXV:QPT's EV-to-FCF is ranked worse than
100% of 376 companies
in the Biotechnology industry
Industry Median: 9.49 vs TSXV:QPT: -8.99

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-22), Quest PharmaTech's stock price is C$0.02. Quest PharmaTech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2023 was C$-0.123. Therefore, Quest PharmaTech's PE Ratio for today is At Loss.


Quest PharmaTech EV-to-FCF Historical Data

The historical data trend for Quest PharmaTech's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quest PharmaTech EV-to-FCF Chart

Quest PharmaTech Annual Data
Trend Jan14 Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.23 -2.87 -12.89 -90.01 -22.46

Quest PharmaTech Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.36 -22.46 -23.05 -25.78 -24.95

Competitive Comparison of Quest PharmaTech's EV-to-FCF

For the Biotechnology subindustry, Quest PharmaTech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quest PharmaTech's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quest PharmaTech's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Quest PharmaTech's EV-to-FCF falls into.



Quest PharmaTech EV-to-FCF Calculation

Quest PharmaTech's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=4.289/-0.477
=-8.99

Quest PharmaTech's current Enterprise Value is C$4.29 Mil.
Quest PharmaTech's Free Cash Flow for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quest PharmaTech  (TSXV:QPT) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Quest PharmaTech's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.02/-0.123
=At Loss

Quest PharmaTech's share price for today is C$0.02.
Quest PharmaTech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.123.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Quest PharmaTech EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Quest PharmaTech's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Quest PharmaTech (TSXV:QPT) Business Description

Traded in Other Exchanges
N/A
Address
8123 Roper Road NW, Edmonton, AB, CAN, T6E 6S4
Quest PharmaTech Inc is a Canadian-based pharmaceutical company developing targeted cancer therapy with its lead product MAb AR9.6, under development for a novel target- truncated O-glycans on MUC16 discovered at the University of Nebraska Medical Center. The company is also developing products utilizing proprietary transdermal delivery technologies with a focus on dermatology and wound healing applications.
Executives
Ragupathy Madiyalakan Director

Quest PharmaTech (TSXV:QPT) Headlines

No Headlines